Epidemiology

You have full text access to this OnlineOpen article

Selenium supplementation and colorectal adenomas: An analysis of the nutritional prevention of cancer trial

  1. Mary E. Reid1,†,*,
  2. Anna J. Duffield-Lillico2,
  3. Annette Sunga1,4,
  4. Marwan Fakih1,
  5. David S. Alberts3,
  6. James R. Marshall1,4

Article first published online: 10 OCT 2005

DOI: 10.1002/ijc.21529

Issue

International Journal of Cancer

International Journal of Cancer

Volume 118, Issue 7, pages 1777–1781, 1 April 2006

Additional Information

How to Cite

Reid, M. E., Duffield-Lillico, A. J., Sunga, A., Fakih, M., Alberts, D. S. and Marshall, J. R. (2006), Selenium supplementation and colorectal adenomas: An analysis of the nutritional prevention of cancer trial. International Journal of Cancer, 118: 1777–1781. doi: 10.1002/ijc.21529

Author Information

  1. 1

    Department of Epidemiology, Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY, USA

  2. 2

    Sloan Kettering Cancer Center, New York, NY, USA

  3. 3

    Arizona Cancer Center, Tucson, AZ, USA

  4. 4

    Department of Social and Preventive Medicine, State University of New York at Buffalo, Buffalo, NY, USA

  1. †

    Fax: +716-845-8487

*Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA

Publication History

  1. Issue published online: 20 JAN 2006
  2. Article first published online: 10 OCT 2005
  3. Manuscript Accepted: 28 JUL 2005
  4. Manuscript Received: 22 MAR 2005

Funded by

  • National Cancer Institute. Grant Number: RO1 CA49764
  • NIH

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (82K)

Keywords:

  • selenium;
  • colorectal cancer;
  • colorectal adenomas

Abstract

Selenium status has been inversely associated with colorectal cancers (CRC) and adenomas. This investigation evaluates the association between selenium supplementation and prevalent and incident colorectal adenomas and CRC detected during the Nutritional Prevention of Cancer trial follow-up. Of the 1,312 randomized to 200 mcg of selenized yeast of matching placebo, 598 participants underwent endoscopic screening (flexible sigmoidoscopy or colonoscopy) for CRC sometime during the follow-up period, which ended in February 1, 1996. There was no colorectal screening performed at baseline. Of those screened, 77% were male (with a mean age of 62.8 years), 42% were former and 25% were current smokers. Adenomas were classified as prevalent (identified at the first endoscopic examination postrandomization during the follow-up period) or incident (identified at the second or subsequent examination). Ninety-nine prevalent and 61 incident adenomas were ascertained. Logistic regression odds ratios (OR) and 95% confidence intervals (CI) were calculated, adjusting for age, gender and smoking status. For prevalent adenomas, there was a suggestive but nonsignificant decrease in risk associated with selenium treatment (OR = 0.67, 95% CI = 0.43–1.05). Subjects in the lowest tertile of baseline selenium (OR = 0.27, 95% CI = 0.09–0.77) and current smokers (OR = 0.27, 95% CI = 0.11–0.66) had significant reductions in risk. The OR for incident adenomas was 0.98 (95% CI = 0.57–1.68). In addition to being associated with a reduced risk of incident CRC, selenium supplementation was associated with a significantly reduced risk of prevalent adenomas, but only among subjects with either a low baseline selenium level or among current smokers. © 2005 Wiley-Liss, Inc.

View Full Article (HTML) Get PDF (82K)